Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a year longer than AstraZeneca's Tagrisso.

1741313316

Reuters

United Kingdom

J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending lives of patients with a type of lung cancer, compared to AstraZeneca's blockbuster drug Tagrisso.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Woodbridge Company

CNBC

Roberts family

United States

J&J says its lung cancer drug combination keeps people alive longer

Johnson &amp; Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a head-to-head study, a finding that could change the standard of care for one of the most deadly tumor types.

Bloomberg

Michael Bloomberg

The Vanguard Group

Howard Buffett

BlackRock

J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for lung cancer, leveraging mucoadhesive protein nanoparticles inspired by the adhesive properties of marine mussels.

Phys.org

Inhalable therapy uses mussel-inspired nanoparticles to target lung cancer cells

The Federal Commission for the Protection against Health Risks (Cofepris) authorized the health records of 210 health inputs, most of which (181) are devices and 10 medicines. 19 clinical trials were also approved, one to check the safety and efficacy of a molecule for the treatment of lung cancer.

La Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) autorizó los registros sanitarios de 210 insumos para la salud, de los cuales la mayoría (181) son dispositivos y 10, medicamentos. También fueron aprobados 19 ensayos clínicos, uno para comprobar la seguridad y eficacia de una molécula para el tratamiento de cáncer de pulmón.

Autorizan fabricar genéricos de fármaco para tratar el cáncer

La Jornada

Mexico

They authorize the manufacture of generic drugs to treat cancer

The J&J bispecific antibody, paired with a Janssen drug, has the potential to become standard treatment for non-small lung cancer patients.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

Johnson & Johnson says its lung cancer drug significantly extended survival

Singular Market Consensus Bank  The US pharmaceutical company has announced that its combined therapy for the treatment of lung cancer has obtained better results than the drug of AstraZeneca which is currently the leader in this treatment in a comparative study, a discovery that could change the standard therapy of one of the tumor types with the highest mortality. According to the study, patients who received J&J treatment lived for a signific…

Consenso del Mercado Singular Bank | La farmacéutica estadounidense ha anunciado que su terapia combinada para el tratamiento del cáncer de pulmón ha obtenido unos mejores resultados que el fármaco de AstraZeneca que es actualmente el líder en este tratamiento en un estudio comparado, un descubrimiento que podría cambiar la terapia estándar de uno de los tipos de tumor con mayor mortalidad. Según el estudio, los pacientes que recibieron el trata…

Noticias Bolsas internacionales La terapia combinada de Johnson & Johnson para el tratamiento del cáncer de pulmón obtiene mejores resultados que el fármaco de AstraZeneca líder en el mercado

Consenso del Mercado

News International Bags Johnson & Johnson Combined Therapy for Lung Cancer Treatment Gets Better Results Than AstraZeneca's Market Leading Drug

The post J&J says lung cancer drugs Rybrevant and Lazcluze extend survival appeared on BitcoinEthereumNews.com. Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful im…

Bitcoin Ethereum News

J&J says lung cancer drugs Rybrevant and Lazcluze extend survival

Niels Wenstedt | Getty Images Johnson & Johnson on Tuesday said the lung cancer regimen keeps people alive at least a year longer than AstraZeneca's Tagrisso, the drug of choice for a certain type of lung cancer. J&J said in a statement that the drugs – Rybrevant and Lazcluze – showed a statistically significant and […]

Daily Expert News

Niels Wenstedt | Getty Images    
Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer. J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at leas…

J&J says its lung cancer drug combination keeps people alive longer

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics